Liver carcinoma
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
HPO |
|
|
|
Liver carcinoma
|
1.000 |
CausalMutation
|
disease |
CGI |
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
(1) To investigate the immunohistochemical expression of the multidrug resistance gene (MDR1) product P-glycoprotein in histological samples from 31 hepatocellular carcinomas (HCCs); and (2) to correlate the results with cell proliferation, p53 expression, the disease-free interval, and cumulative patient survival.
|
8763260 |
1996 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma.
|
16048565 |
2005 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Hepatocellular carcinoma (HCC) is one of the most frequent-occurring malignant tumours worldwide, but molecular changes of tumour DNA, with the exception of viral integrations and p53 mutations, are poorly understood.
|
11531255 |
2001 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Hepatocellular carcinoma is sometimes associated with p53 dysfunction and decreased p21(WAF1) expression.
|
12217602 |
2002 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
HCC from high-incidence regions showing also a high prevalence of a specific Ser-249 TP53 mutation is one of the most striking examples of a mutagen fingerprint.
|
12673364 |
2003 |
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
HCC was common in males than in females (2.6:1, P<0.05) and with hepatitis C virus than hepatitis B virus infection (77.1% vs. 18.7%, P=0.001). p53 expression was found in DN (3/23) and HCC (12/48).
|
15566504 |
2004 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Hepatocellular carcinoma (HCC) cells display inactivating mutations of p53 and epigenetic silencing of p16(INK4a).
|
19070423 |
2009 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
HCC cell lines (HepG2, Hep3B and MHCC97L) and normal liver cell line (L02) with a different p53 status were infected with SG600-IL24 and Ad.IL-24, respectively.
|
20872968 |
2010 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Hepatocellular carcinoma (HCC) emerges when senescence is bypassed. tp53 mutation both alleviates senescence and accelerates tumor onset.
|
24486181 |
2014 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure?
|
9189703 |
1997 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations were detected in 12 (27%) of 44 HCCs with HCV and 2 (14%) of 14 SVR-HCCs.
|
18492017 |
2009 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations, particularly the hot spot mutations R249S and V157F, are associated with poor prognosis for patients with HCC.
|
21094160 |
2011 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations, particularly the hot spot mutations R249S and V157F, are associated with poor prognosis for patients with HCC.
|
21616106 |
2011 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.
|
22759751 |
2012 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 exon 7 mutations, which are related to aflatoxins exposure, were found at 14.6% (249ser), 7.3% (250leu) and 2.4% (250ser) in 41 cases of HCC and 1.4% in 74 liver cirrhosis (without HCC) cases, suggesting a moderate dietary exposure to aflatoxins in the Espírito Santo State, Brazil.
|
23649769 |
2013 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 and CTNNB1 are the next most prevalent mutations, affecting 25%-30% of HCC patients, that, in addition to low-frequency mutated genes (eg, AXIN1, ARID2, ARID1A, TSC1/TSC2, RPS6KA3, KEAP1, MLL2), help define some of the core deregulated pathways in HCC.
|
26099527 |
2015 |
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
TP53/MicroRNA Interplay in Hepatocellular Carcinoma.
|
27918441 |
2016 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation resulted in the downregulation of the immune response in HCC.
|
30885723 |
2019 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations occurred far less frequently in our pediatric HCC cohort than reported in adult cohorts.
|
30977242 |
2019 |
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations observed in hepatocellular carcinoma are accompanied by a loss of wild-type p53 function.
|
9769950 |
1997 |